- Tryp Therapeutics is a pharmaceutical company focused on developing new potential treatments for medical conditions with unmet needs
- The company’s current lead candidates for drug development are a synthetic psychedelic for treating fibromyalgia and eating disorders
- Tryp’s efforts to develop a psychedelic drug candidate are part of a broader scientific movement to use various mind-altering drugs to treat select neurological conditions when paired with the care of a trained therapist
- The company has been preparing to initiate a Phase 2a clinical trial for the psychedelic candidate in partnership with a medical research team at the University of Florida
The idea of using psychedelic, mind-tripping drugs as pharmaceuticals to help improve the quality of people’s lives no longer seems as far out as it once might have during the heyday of the multinational war on drugs. An increasing cadre of investigational science efforts are utilizing psychedelics to determine their potential in creating better medicine for select conditions with neurological-based maladies.
San Diego-based pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is turning its own investigational machinery toward the development of drug candidates TRP-8802, a synthetic psilocybin formulation being aimed at…
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.